BamSEC and AlphaSense Join Forces
Learn More

Prothena Corporation plc

NASDAQ: PRTA    
Share price (1/8/25): $14.16    
Market cap (1/8/25): $762 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 2 pages Chad J. Swanson, PH.D. September 27, 2024
12/34/56
EX-10.1
from 10-Q 9 pages Consulting Agreement
12/34/56
EX-10.3
from 10-Q 109 pages Global License Agreement
12/34/56
EX-10.1
from 8-K 1 page Fifth Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan
12/34/56
EX-10.2
from 10-Q 10 pages Sent by Email as Pdf January 16, 2024 Prothena Biosciences Limited 77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin 2, D02 Vk60, Ireland Attn: Company Secretary Re: [***] Dear Ms. Yvonne Tchrakian
12/34/56
EX-10.1
from 10-Q 3 pages David Ford February 12, 2024
12/34/56
EX-10.23
from 10-K 14 pages First Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan
12/34/56
EX-10.2
from 10-Q 77 pages Global License Agreement
12/34/56
EX-10.1
from 10-Q 8 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 1 page Fourth Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan
12/34/56
EX-10.1
from 10-Q 1 page Fourteenth Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan
12/34/56
EX-10.22
from 10-K 13 pages First Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan
12/34/56
EX-10.15(B)
from 10-K 8 pages Consent to Sublease Agreement
12/34/56
EX-10.15(A)
from 10-K 17 pages This Sublease (This “Sublease”) Is Dated for Reference Purposes as of October 28, 2022 (The “Effective Date”), and Is Made by and Between Arcus Biosciences, Inc., a Delaware Corporation (“Sublessor”), and Prothena Biosciences Inc, a Delaware Corporation (“Sublessee”). Sublessor and Sublessee Hereby Agree as Follows
12/34/56
EX-10.4
from 10-Q 8 pages Consulting Agreement
12/34/56
EX-10.1
from 8-K 1 page Third Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan
12/34/56
EX-10.20
from 10-K 11 pages First Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan
12/34/56
EX-10.5
from 10-Q 76 pages U.S. License Agreement
12/34/56
EX-10.4
from 10-Q 81 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Both Not Material and the Type of Information That the Registrant Customarily and Actually Treats as Private and Confidential. Share Purchase Agreement by and Between Novo Nordisk a/S; Novo Nordisk Region Europe a/S; Prothena Corporation plc; and Prothena Biosciences Limited Dated as of July 8, 2021
12/34/56
EX-10.3
from 10-Q 4 pages [***] Certain Information in This Document Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10). Such Excluded Information Is Both Not Material and the Type of Information That the Registrant Customarily and Actually Treats as Private and Confidential. Amendment No. 2 to License, Development, and Commercialization Agreement
12/34/56